{"id":"NCT05028634","sponsor":"Celgene","briefTitle":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","officialTitle":"A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-β or No Disease Modifying Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-11","primaryCompletion":"2023-11-15","completion":"2023-11-15","firstPosted":"2021-08-31","resultsPosted":"2025-01-22","lastUpdate":"2025-02-11"},"enrollment":63,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"BIOLOGICAL","name":"Tetanus, diphtheria, and acellular pertussis vaccine","otherNames":["Tdap"]},{"type":"BIOLOGICAL","name":"Pneumococcal polysaccharide vaccine","otherNames":["PPSV23"]},{"type":"BIOLOGICAL","name":"Seasonal influenza vaccine","otherNames":[]}],"arms":[{"label":"Cohort 1 - Ozanimod","type":"EXPERIMENTAL"},{"label":"Cohort 1 - non-pegylated interferon-β or no disease modifying therapy","type":"EXPERIMENTAL"},{"label":"Cohort 2 - Ozanimod","type":"EXPERIMENTAL"},{"label":"Cohort 2 - non-pegylated interferon-β or no disease modifying therapy","type":"EXPERIMENTAL"}],"summary":"This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no disease modifying therapies (DMTs). The data of this study will support the labels for ozanimod in multiple sclerosis (MS) because the effect of ozanimod on the vaccination response of MS participants is of interest to participants and prescribers.","primaryOutcome":{"measure":"Percentage of Participants Meeting Immune Serological Response Criteria to Tetanus Toxoid Antigen","timeFrame":"Day 28","effectByArm":[{"arm":"Ozanimod","deltaMin":10,"sd":null},{"arm":"Non-Ozanimod","deltaMin":53.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":6},"locations":{"siteCount":33,"countries":["United States","Germany"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Injection site pain","Fatigue","COVID-19","Urinary tract infection"]}}